Botulism - Pediatrics

Overview

Forms of Botulism

Infant Botulism (Most Important Pediatric Form)

Pathophysiology

• Infant ingests spores (not preformed toxin) from soil/dust or honey
• Because the infant gut lacks mature competitive microbiota, spores germinate, colonize the large intestine, and produce botulinum toxin in situ
• Toxin is absorbed into the circulation and transported to peripheral cholinergic nerve terminals
• Toxin irreversibly cleaves SNARE proteins, preventing vesicular release of acetylcholine
• Recovery only occurs when new nerve terminals sprout (weeks to months)

Why infants are uniquely susceptible

• Immature intestinal microflora cannot competitively exclude C. botulinum
• Adults have established gut flora that prevents colonization

Epidemiology

• Between 2001 and 2019, 2,172 infant botulism cases were reported in the US
• Toxin serotypes: B (58%), A (40%), rarely E or F
• Rare strains producing two serotypes (A+B or B+F) have been documented
• Mortality in documented infant cases: 1-2% (with good supportive care)
• Some SIDS deaths may represent unrecognized rapidly progressive infant botulism

Sources of Spore Exposure

• Soil and household dust - now the most common identified source
• Honey - a well-established, avoidable source; honey should never be given to infants under 1 year
• Infant milk powder (rare)
• No case of infant botulism has been proven to result from corn syrup

Clinical Features

Infant Botulism Presentation

1. Constipation - often the first sign (3-30 days incubation after spore ingestion)
2. Poor feeding - weak suck
3. Weak cry
4. Loss of facial expression (cranial nerve VII palsy)
5. Diminished gag reflex
6. Ocular palsies - ptosis, ophthalmoplegia (diplopia if older child)
7. Loss of head control
8. Progressive descending, symmetric, flaccid paralysis
9. Hypotonia - generalized
10. Autonomic signs - dilated pupils, dry mouth, urinary retention, hyperthermia

Key features: Afebrile, alert, no sensory deficits, descending paralysis

Distinction from Myasthenia Gravis

• Botulism does affect the pupils (dilated, unreactive) - MG does not
• Botulism produces autonomic signs - MG does not

Progression

• Paralysis descends: cranial nerves → neck/shoulders → upper limbs → lower limbs
• Proximal muscle groups affected before distal
• Respiratory failure from diaphragm and accessory muscle paralysis is the life-threatening complication

Diagnosis

Clinical Basis

• Diagnosis is primarily clinical - symmetric descending flaccid paralysis, afebrile, alert
• Do not wait for lab confirmation before starting treatment

Laboratory Tests

If suspected, contact state health department (24-hour service) immediately - they coordinate testing and antitoxin release.

Treatment

1. Supportive Care (Foundation of Management)

• Airway and respiratory support - mechanical ventilation may be required for months
• Nutritional support (NG/NJ feeds)
• Recovery takes weeks to months

2. Antitoxin - Infant Botulism (< 1 year)

• FDA-licensed specifically for infant botulism caused by type A or type B
• Human-derived - eliminates serum sickness risk
• Produced and distributed by the California Department of Public Health (24-hr: 510-231-7600; infantbotulism.org)
• Significantly reduces: days of mechanical ventilation, ICU stay, and total hospital stay by ~1 month
• Cost-saving
• First-line therapy for naturally occurring infant botulism
• Delay live-virus vaccines for 6 months after BabyBIG (interference with immune response)

• FDA-licensed 2013 for adult and pediatric botulism
• Covers serotypes A-G
• Used for type F infant botulism (not covered by BabyBIG)
• Available through the CDC Emergency Operations Center (770-488-7100)
• "Despeciated" product (>90% Fab/F(ab')2 fragments) to reduce serum sickness

Key principle: Antitoxin ends toxemia and prevents further toxin uptake, but does NOT reverse existing paralysis - administer as early as possible.

3. Antibiotics

• Do NOT use antibiotics in infant botulism unless there is a clear concurrent infection
• Aminoglycosides are contraindicated - potentiate the paralytic effects of botulinum toxin
• For wound botulism: consider delaying antibiotics until antitoxin is given (theoretical risk of toxin release from bacterial cell lysis)

4. GI Decontamination

• If contaminated food may still be in the GI tract: enema to remove residual toxin/spores
• Cathartics/laxatives are not recommended

Differential Diagnosis of "Floppy Infant"

• Infant botulism
• Spinal muscular atrophy (SMA type 1)
• Myasthenia gravis (neonatal or congenital)
• Guillain-Barre syndrome (ascending, not descending)
• Hypotonic cerebral palsy
• Sepsis/meningoencephalitis
• Hypothyroidism
• Metabolic disorders (hypocalcemia, hypomagnesemia)

Prevention

• Never give honey to infants under 1 year of age
• No established prevention for soil/dust exposure (universal)
• No vaccine currently available for general use
• Breastfeeding does not prevent infant botulism (cases occur in breastfed infants), but breast milk may offer some protective microbiome effect

Key Summary Points for Exams

Subacute Sclerosing Panencephalitis (SSPE) - Pediatrics

Definition

Etiology and Pathogenesis

• After primary measles infection, the virus persists in neurons and glial cells in an intracellular, non-productive form
• Defective Matrix (M) protein and other envelope proteins are defective or absent - the virus cannot assemble and bud properly
• As a result, the virus cannot produce infectious virions - it spreads only by cell-to-cell contact
• The virus evades immune clearance by remaining intracellular
• Large numbers of viral nucleocapsids accumulate in neurons and glia
• Antibody to M protein is characteristically absent in patients' serum (unlike other measles antibodies which are markedly elevated)
• The restricted viral gene expression in differentiated brain cells is key to maintaining the persistent infection

Epidemiology

Important: Risk of SSPE is highest when measles occurs in infancy (<2 years). This is a major reason for timely measles vaccination.

A 2024 review (PMID 38477320) in J Child Neurol and a 2025 review (PMID 40701692) in Semin Pediatr Neurol both warn that rising vaccine hesitancy may lead to a resurgence of SSPE cases in coming decades.

Clinical Stages

Stage I - Behavioral/Cognitive Changes

• Declining school performance
• Personality and mood changes, temper outbursts
• Difficulty with language
• Loss of interest in usual activities
• No fever, no headache (distinguishes from acute viral encephalitis)

Stage II - Motor/Neurological

• Myoclonus - the hallmark; often bilateral, massive, shock-like jerks
• Focal or generalized seizures
• Progressive intellectual deterioration
• Ataxia
• Chorioretinitis - visual disturbances, retinal lesions
• Choreoathetoid or ballistic movements
• Spasticity begins

Stage III - Deterioration

• Optic atrophy
• Quadriparesis
• Autonomic instability
• Progressive unresponsiveness
• Akinetic mutism

Stage IV - Terminal

• Coma - child lies insensate, virtually "decorticated"
• Vegetative state
• Death (usually from intercurrent infection or autonomic failure)

Diagnosis

Clinical

• History of primary measles before age 2, followed by 6-8 year asymptomatic period
• Progressive neurological decline beginning with behavioral changes and myoclonus
• Absence of fever (key distinguishing feature)

EEG - Pathognomonic Pattern

• Bursts of high-voltage, generalized sharp-slow wave complexes
• Occurring every 3-8 seconds (some sources: every 5-8 seconds)
• Each complex lasting up to 3 seconds
• Against a background of depressed/flat activity
• Initially only nonspecific slowing; periodic complexes appear in Stage II
• Bisynchronous (both hemispheres simultaneously)

CSF Analysis

Serology

• Markedly elevated measles antibody titers in both serum and CSF
• Anti-M (matrix) protein antibody is characteristically absent
• The elevated antibody paradoxically coexists with progressive disease (immune response cannot clear the infection)

MRI

• Often normal early in disease
• As disease progresses: high T2/FLAIR signal in gray matter and subcortical/periventricular white matter, beginning in posterior hemispheres
• Cortical atrophy in advanced cases

Histopathology (Brain Biopsy/Autopsy)

• Eosinophilic intranuclear and intracytoplasmic inclusions in neurons and glial cells (Cowdry type A inclusions) - the histopathologic hallmark
• Destruction of nerve cells and neuronophagia
• Perivascular cuffing with lymphocytes and mononuclear cells
• Demyelination of white matter (hence "sclerosing")
• Fibrous gliosis
• Electron microscopy: viral nucleocapsids in inclusion-bearing cells

Diagnostic Criteria (Presumptive)

1. Periodic complexes on EEG
2. Elevated CSF gamma globulin and oligoclonal bands
3. Elevated measles antibody titers in serum and CSF

• Measles virus culture from brain tissue (special cocultivation techniques)
• Viral antigen by immunocytochemistry
• Viral genome by in situ hybridization or PCR

Treatment

Available Treatments (Palliative/Disease-Modifying)

No treatment has been subjected to a controlled clinical trial. The laboratory endpoint of treatment is eradication of detectable measles antigen from the CSF.

Supportive Care

• Anticonvulsants for seizures
• Nutritional support
• Prevention of complications (aspiration, pressure ulcers, infections)

Prevention

• First dose at 12-15 months of age
• Second dose at 4-6 years
• MMRV (measles, mumps, rubella, varicella) is an alternative combination
• The introduction and widespread use of measles vaccine has practically eliminated SSPE in vaccinated populations

Because SSPE risk is highest in infants who get measles before age 2, timely vaccination of infants is critical. Children of vaccine-hesitant parents who contract measles are at the highest risk of developing SSPE years later.

Differential Diagnosis

Key Summary Points for Exams